EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Epigenetic demethylation sensitizes cancer cells to CAR-M triggered pyroptosis and remodels inflammatory immune responses in the tumor microenvironment to potentiate CAR-M cell therapy

Wenhui Chu, Yuanhui Xu, Liting Lin, Zixuan Ye, Meixi Jiang, Yuanyuan Li, Xiaoya Deng, Ziqi Qiuzhuo, Yuqiong Xia, Xianghan Zhang, Lili Jiang, Lin Gu und 2 weitere

Journal for ImmunoTherapy of Cancer · 2026-10 · 14 (10) · e015535

DOI: 10.1136/jitc-2026-015535 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 30.10.2026. Verfasst von Wenhui Chu und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science and Technology, Xidian University, Xi'an, China. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Beijing Xisike Clinical Oncology Research Foundation, Key Research and Development Program of Shaanxi, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tumor epigenetic reprogramming serves as a critical hallmark of cancer, fostering transcriptional plasticity of gene expression and driving alterations in the suppressive inflammatory responses within the tumor microenvironment, which pose significant challenges to the advancement of novel CAR-macrophage (CAR-M)-based antitumor therapies. However, it remains limited mechanistic investigations exploring how epigenetic reprogramming strategies impact the efficacy of CAR-M treatments.

Methods

Human epidermal growth factor receptor 2 (HER2)-targeted CAR-Ms containing either an α1β1 integrin-mediated Fc-gamma receptor I (FcγRI) or CD3ζ signaling domain were generated and compared for tumor-directed migration and antitumor activity. HER2-positive tumor cells were pretreated with decitabine (DAC). CAR-M function, tumor-cell death, transcriptomic and inflammatory pathway changes, tumor immune remodeling, and therapeutic efficacy were assessed using in vitro assays, RNA sequencing, and murine tumor and metastasis models. Full-dose and half-dose CAR-M regimens were evaluated.Results α1β1 integrin-FcγRI CAR-Ms displayed significantly greater migration toward HER2-positive tumor cells than CD3ζ CAR-Ms. DAC potentiated anti-HER2 CAR-M activity by reprogramming tumor-cell gene expression and shifting the dominant cell-death mode from apoptosis to gasdermin E (GSDME)-dependent pyroptosis. RNA sequencing demonstrated enrichment of inflammatory immune-response programs, including nuclear factor kappa B and Janus kinase-signal transducer and activator of transcription signaling, after DAC treatment. DAC also favorably remodeled the tumor immune microenvironment, thereby supporting CAR-M activity. In murine models, DAC plus CAR-M therapy enhanced inflammatory antitumor immunity and improved control of primary tumor growth and metastatic disease compared with CAR-M monotherapy. Notably, DAC pretreatment combined with half-dose CAR-Ms achieved therapeutic efficacy comparable to that of full-dose CAR-M treatment.

Conclusions

DAC-mediated DNA demethylation sensitizes HER2-positive tumors to CAR-M therapy through GSDME-dependent pyroptosis, activation of inflammatory signaling, and favorable remodeling of the tumor microenvironment. Epigenetic priming may improve CAR-M efficacy while reducing the required cell dose, supporting further translational development of this combination strategy for solid tumors.

Schlagwörter

Stichwörter der Autor:innen

Chimeric antigen receptor - CARCombination therapyGastric CancerImmunotherapyMacrophage

Autor:innen und Institutionen

  • School of Life Science and Technology, Xidian University, Xi'an, China.
  • Engineering Research Center of Molecular & Neuroimaging, Xidian University, Xi'an, China.
  • Department of Gastrointestinal Surgery Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
  • The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Shaanxi Provincial Hospital of Traditional Chinese Medicine, Xi'an, China.
  • School of Life Science and Technology, Xidian University, Xi'an, China pbning@xidian.edu.cn chzhhui@mail.sysu.edu.cn.

Förderung

  • Beijing Xisike Clinical Oncology Research Foundation
  • Key Research and Development Program of Shaanxi
  • National Natural Science Foundation of China
  • Guangxi Natural Science Foundation
  • National Natural Science Foundation of Shaanxi Province
  • Dual-chain Integration Special Program of Qinchuangyuan Construction
  • Original Exploration Project of National Natural Science Foundation of China

Zitieren

APA

Chu, W., Xu, Y., Lin, L., Ye, Z., Jiang, M., Li, Y., Deng, X., Qiuzhuo, Z., Xia, Y., Zhang, X., Jiang, L., Gu, L., Ning, P., & Chen, Z. (2026). Epigenetic demethylation sensitizes cancer cells to CAR-M triggered pyroptosis and remodels inflammatory immune responses in the tumor microenvironment to potentiate CAR-M cell therapy. Journal for ImmunoTherapy of Cancer, 14(10), e015535. https://doi.org/10.1136/jitc-2026-015535

Vancouver

Chu W, Xu Y, Lin L, Ye Z, Jiang M, Li Y, et al. Epigenetic demethylation sensitizes cancer cells to CAR-M triggered pyroptosis and remodels inflammatory immune responses in the tumor microenvironment to potentiate CAR-M cell therapy. Journal for ImmunoTherapy of Cancer. 2026;14(10):e015535. doi:10.1136/jitc-2026-015535

BibTeX
@article{Chu2026,
  author = {Chu, Wenhui and Xu, Yuanhui and Lin, Liting and Ye, Zixuan and Jiang, Meixi and Li, Yuanyuan and Deng, Xiaoya and Qiuzhuo, Ziqi and Xia, Yuqiong and Zhang, Xianghan and Jiang, Lili and Gu, Lin and Ning, Pengbo and Chen, Zhihui},
  title = {Epigenetic demethylation sensitizes cancer cells to CAR-M triggered pyroptosis and remodels inflammatory immune responses in the tumor microenvironment to potentiate CAR-M cell therapy},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {10},
  pages = {e015535},
  doi = {10.1136/jitc-2026-015535}
}
Kostenlos starten →